Wave Life Sciences Reports Positive Interim Data for Duchenne Muscular Dystrophy Treatment
Wave Life Sciences, Duchenne Muscular Dystrophy, DMD, Exon 53 Skipping, WVE-N531, FORWARD-53 Clinical Trial, Interim Data, Muscle Health, Dystrophin Expression
UCB and Biogen Announce Positive Phase 3 Results for Dapirolizumab Pegol in Systemic Lupus Erythematosus, Plan Second Phase 3 Trial
UCB, Biogen, Dapirolizumab Pegol, Systemic Lupus Erythematosus, Phase 3 Trial, PHOENYCS GO, PHOENYCS FLY
Astellas’ Vyloy (Zolbetuximab) Receives EU Approval for Advanced Gastric and Gastroesophageal Junction Cancer Treatment
Astellas, Vyloy, Zolbetuximab, EU Approval, Gastric Cancer, Gastroesophageal Junction Cancer, Claudin 18.2, Targeted Therapy
Aptadir Therapeutics Unveils Novel RNA Inhibitors to Combat Cancer and Genetic Disorders
Aptadir Therapeutics, RNA inhibitors, DNMT1 interacting RNAs (DiRs), Cancer treatment, Genetic diseases, Epigenetic targeting, RNA therapeutics
Metsera’s Long-Acting GLP-1 Drug Shows Promising 7.5% Weight Loss in 36 Days, Paving Way for Monthly Dosing
Metsera, GLP-1, obesity treatment, long-acting drug, weight loss, monthly dosing, MET-097, clinical trial results.
Bristol Myers Squibb Continues Layoffs in New Jersey, Cutting 79 More Jobs
Bristol Myers Squibb, BMS layoffs, New Jersey layoffs, pharmaceutical industry layoffs, cost-savings measures
AI Guidance for Investors: Navigating the Future with Strategic Approaches and Regulatory Insights
AI Guidance for Investors, Strategic AI Adoption, Regulatory Impact on AI, Cybersecurity Risks in AI, AI Mapping Strategies, Data Governance in AI, Future of AI in Healthcare
Biohaven Achieves Breakthrough in Spinocerebellar Ataxia Treatment with Positive Pivotal Study Results for Troriluzole
Biohaven, Troriluzole, Spinocerebellar Ataxia (SCA), Pivotal Study Results, Neurodegenerative Disease, FDA Submission, New Drug Application (NDA)
Biohaven Revives Troriluzole Hopes with Positive Update for Spinocerebellar Ataxia
Troriluzole, Spinocerebellar Ataxia (SCA), Biohaven Pharmaceuticals, Neurodegenerative Disorders, FDA New Drug Application (NDA), Clinical Trials, Rare Diseases
Telix Acquires RLS to Bolster Radiopharmaceutical Manufacturing and Distribution in North America
Telix Pharmaceuticals, RLS (USA) Inc., radiopharmaceutical manufacturing, distribution, acquisition, North America, radiometal production network